Search

Ethinylestradiol

Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]

Lymecycline

It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961.

Autologous cultured chondrocytes

It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

Gefitinib

Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Penpulimab

The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

Grapiprant

Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

Turoctocog alfa

[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

Chlorphenesin

Plantago seed

Regardless, this agent is most predominantly used as a gentle laxative agent in many parts of the world that is more commonly referred as psyllium or psyllium husk. … Its potential benefit in maintaining remission in ulcerative colitis has been studied [A27156].

Cilgavimab

[L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Certain SARS-CoV-2 Omicron subvariants may be associated with resistance to monoclonal antibodies, such as EVUSHELD.